Gene Solutions

Multi-Cancer Early Detection at a Turning Point: What Comes Next? Multi-cancer detection, or MCD, is being evaluated as a new approach to screening for multiple cancer types through a single blood test. Often described in the screening setting as multi-cancer early detection, or MCED, the field has now reached an important U.S. FDA regulatory milestone, bringing both its potential - and the evidence needed to support the promise of “early” detection - into sharper focus. We are honored to welcome Prof. Umberto Malapelle, President of the International Society of Liquid Biopsy and Chair of the Predictive Molecular Pathology Laboratory at the University of Naples Federico II, as Co-Chair and Speaker at the Gene Solutions Industry Satellite Symposium during ESMO - European Society for Medical Oncology Congress 2026. Presentation topic: Clinical Challenges with Multi-Cancer Early Detection Tests: Unmet Needs and Lessons for Next-Generation Approaches in Precision Oncology “Multi-cancer early detection is reaching an important turning point, with the potential to become a new category in cancer screening. First-generation of data have shown both the promise of MCED and the challenges that remain, particularly in detecting cancer at its earliest stages, understanding performance across cancer types, and guiding the diagnostic pathway after a positive result. The next generation must build on these lessons through stronger biological signals, robust clinical validation, and clear integration with established screening.” Join Prof. Umberto Malapelle as he opens the symposium with an expert perspective on the clinical challenges facing current MCED tests, the evidence shaping regulatory and clinical discussions, and the lessons guiding next-generation approaches in precision oncology. 👇 Gene Solutions Industry Satellite Symposium ▪️Topic: AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation ▪️Date: Friday, 23 October 2026 ▪️Time: 09:45–11:15 CEST ▪️Location: Salamanca Auditorium, Hall 10 🔗 Register now to stay up to date with the latest scientific insights from Gene Solutions’ Industry Satellite Symposium at ESMO Congress 2026: https://lnkd.in/gWq27EKW 🔗 ESMO session link: https://lnkd.in/dGWkW9Um #ESMO26 #LiquidBiopsy #MCED #PrecisionOncology #GeneSolutions This non-promotional medical educational symposium is organized and funded by Gene Solutions for healthcare professionals only.

Decoding Tumor-Immune Interactions Through Multi-Omic Signals The future of precision oncology depends not only on identifying genomic alterations, but also on understanding how tumor biology interacts with the immune system. At the Gene Solutions Industry Satellite Symposium during ESMO - European Society for Medical Oncology Congress 2026, Prof. Aya El Helali of The University of Hong Kong, Hong Kong SAR, will explore how multi-omic signals can deepen our understanding of cancer biology and support immunogenetic discovery. Presentation topic: The Role of Multi-Omic Signals for Next Generation Precision Oncology and Immunogenetic Discovery “The next frontier of precision oncology lies in deciphering the complex interplay between tumor biology and the immune system. By integrating genomic, transcriptomic, and immunogenetic information, multi-omic profiling can help characterize neoantigen profiles, the tumor microenvironment, and immune checkpoint expression. These deeper insights may open new directions for biomarker discovery and more personalized therapeutic strategies.” Drawing on ongoing research and multi-omic analyses, Prof. Aya El Helali will discuss how immunogenetic insights may contribute to biomarker discovery, therapeutic research, and the next generation of precision oncology. Join Prof. Aya El Helali for a forward-looking discussion on how deeper molecular intelligence can help reveal the relationship between tumor biology and the immune system, bringing precision oncology closer to more individualized therapeutic strategies. 👇Gene Solutions Industry Satellite Symposium ▪️Topic: AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation ▪️Date: Friday, 23 October 2026 ▪️Time: 09:45–11:15 CEST ▪️Location: Salamanca Auditorium, Hall 10 🔗 Register now to stay up to date with the latest scientific insights from Gene Solutions’ Industry Satellite Symposium at ESMO Congress 2026: https://lnkd.in/gWq27EKW 🔗 ESMO session link: https://lnkd.in/dGWkW9Um #ESMO26 #PrecisionOncology #MultiOmics #Immunogenetics #Neoantigens #TumorMicroenvironment #CancerResearch #GeneSolutions This non-promotional medical educational symposium is organized and funded by Gene Solutions for healthcare professionals only.

Decoding Tumor-Immune Interactions Through Multi-Omic Signals The future of precision oncology depends not only on identifying genomic alterations, but also on understanding how tumor biology interacts with the immune system. At the Gene Solutions Industry Satellite Symposium during ESMO - European Society for Medical Oncology Congress 2026, Prof. Aya El Helali of The University of Hong Kong, Hong Kong SAR, will explore how multi-omic signals can deepen our understanding of cancer biology and support immunogenetic discovery. Presentation topic: The Role of Multi-Omic Signals for Next Generation Precision Oncology and Immunogenetic Discovery “The next frontier of precision oncology lies in deciphering the complex interplay between tumor biology and the immune system. By integrating genomic, transcriptomic, and immunogenetic information, multi-omic profiling can help characterize neoantigen profiles, the tumor microenvironment, and immune checkpoint expression. These deeper insights may open new directions for biomarker discovery and more personalized therapeutic strategies.” Drawing on ongoing research and multi-omic analyses, Prof. Aya El Helali will discuss how immunogenetic insights may contribute to biomarker discovery, therapeutic research, and the next generation of precision oncology. Join Prof. Aya El Helali for a forward-looking discussion on how deeper molecular intelligence can help reveal the relationship between tumor biology and the immune system, bringing precision oncology closer to more individualized therapeutic strategies. 👇Gene Solutions Industry Satellite Symposium ▪️Topic: AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation ▪️Date: Friday, 23 October 2026 ▪️Time: 09:45–11:15 CEST ▪️Location: Salamanca Auditorium, Hall 10 🔗 Register now to stay up to date with the latest scientific insights from Gene Solutions’ Industry Satellite Symposium at ESMO Congress 2026: https://lnkd.in/gNAtBb5D 🔗 ESMO session link: https://lnkd.in/dGWkW9Um #ESMO26 #PrecisionOncology #MultiOmics #Immunogenetics #Neoantigens #TumorMicroenvironment #CancerResearch #GeneSolutions This non-promotional medical educational symposium is organized and funded by Gene Solutions for healthcare professionals only.

Liquid Biopsy in Practice: Real-World Evidence from Asia How is liquid biopsy moving from scientific innovation into real-world cancer care? At the Gene Solutions Industry Satellite Symposium during ESMO - European Society for Medical Oncology Congress 2026, Prof. Herbert Loong, MBBS FRCP FASCO of The Chinese University of Hong Kong will share clinical evidence and experience from Asia on the expanding applications of multi-omic liquid biopsy for patients with cancer. With internationally recognized expertise in thoracic oncology, sarcoma, experimental therapeutics, and health economics, Prof. Loong brings a practical perspective on how molecular profiling and longitudinal ctDNA monitoring can support clinical decisions across the cancer journey. “Tissue remains central to cancer diagnosis, but it provides a snapshot in space and time that may not fully capture tumor heterogeneity. Liquid biopsy can complement tissue profiling across applications, from longitudinal ctDNA monitoring for molecular residual disease and treatment response to the detection of emerging resistance mutations over time. Published studies and real-world experience from Asia are helping us understand how multi-omic liquid biopsy technologies can enable more precise and broader detection while remaining accessible at scale. Stay tuned for more on what I’ll be sharing at the ESMO Industry Satellite Symposium.” Join Prof. Loong for practical insights into expanding access to high-precision liquid biopsy across diverse healthcare settings. 👇 Gene Solutions Industry Satellite Symposium ▪️Topic: AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation ▪️Date: Friday, 23 October 2026 ▪️Time: 09:45–11:15 CEST ▪️Location: Salamanca Auditorium, Hall 10 🔗 Register now to stay up to date with the latest scientific insights from Gene Solutions’ Industry Satellite Symposium at ESMO Congress 2026: https://lnkd.in/gNAtBb5D 🔗 ESMO session link: https://lnkd.in/dGWkW9Um #ESMO26 #LiquidBiopsy #MCED #PrecisionOncology #GeneSolutions

ESMO - European Society for Medical Oncology ESMO 2026: One Symposium. The Full Cancer Care Continuum. From earlier cancer detection to precision oncology — treatment-response assessment, molecular recurrence monitoring, immunogenetic discovery, and functional tumour modelling, liquid biopsy and multi-omic technologies are opening new possibilities across cancer care. Join us at the Gene Solutions Industry Satellite Symposium during ESMO Congress 2026: AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation Together with international experts, the symposium will bring diverse scientific and clinical perspectives across the cancer care continuum: - Clinical challenges and unmet needs shaping the next generation of multi-cancer early detection - Technology principles, large validation datasets, and implementation pathways for AI-enabled multi-omic cfDNA profiling - An integrated precision-oncology approach using multi-omic liquid biopsy: Asian real-world evidence, and high-precision applications from integrated tissue genomic and transcriptomic profiling to longitudinal tumor informed and naive liquid biopsy monitoring for molecular residual disease and treatment response to the detection of emerging resistance mutations - The role of multi-omic signals in next-generation precision oncology and immunogenetic discovery — integrating genomic, transcriptomic, and immune readouts to characterise neoantigen profiles, the tumour microenvironment, and immune-checkpoint expression, and to support immunotherapy biomarker discovery and neoantigen vaccine development - The potential of patient-derived 3D tumor organoids to add a functional dimension to precision oncology 📅 Friday, 23 October 2026 🕘 09:45–11:15 CEST 📍 Salamanca Auditorium, Hall 10, IFEMA Madrid 🔗 Register to receive symposium updates: https://lnkd.in/gNAtBb5D 🔗 Read the symposium announcement: https://lnkd.in/dfw2jFmW 🔗 View the session in the ESMO programme: https://lnkd.in/dGWkW9Um Stay tuned as we introduce the international experts joining the symposium and share their perspectives on the future of multi-omic cancer care. #ESMO26 #LiquidBiopsy #PrecisionOncology #MultiOmics #MCED #ctDNA #MRD #GenomicProfiling #Organoids #RealWorldEvidence This non-promotional medical educational symposium is organized and funded by Gene Solutions for healthcare professionals only.

ESMO - European Society for Medical Oncology Multi-omic liquid biopsy will reshape clinical practice only when it moves from technological innovation to evidence-based decisions that health systems can implement at scale. This is the focus of the ESMO 2026 Industry Satellite Symposium hosted by Gene Solutions: AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation Co-chairs: Prof. Herbert Loong, MBBS FRCP FASCO, The Chinese University of Hong Kong, Hong Kong SAR. Prof. Umberto Malapelle, University Federico II of Naples, Italy. The session will address the clinical challenges of current multi-cancer early detection tests; the validation of AI-enabled multi-omic cfDNA approaches and pathways to implementation in diverse settings; Asian real-world evidence on ctDNA MRD monitoring and profiling at scale, with an emphasis on affordability and high-precision applications; multi-omic signals for next-generation precision oncology and immunogenetic discovery; and complementary translational models, including 3D patient-derived organoids. The session will conclude with a panel discussion on bridging regional evidence to global practice. 🗓️ Friday, 23 October 2026 ⏳09:45–11:15 CEST 📍Salamanca Auditorium, Hall 10, IFEMA Madrid Faculty also includes Dr. Le Son Tran and Dr. Vien Le (Medical Genetics Institute, Viet Nam), Prof. Aya El Helali (The University of Hong Kong), and Asst. Prof. Lucksamon Thamlikitkul (Siriraj Hospital, Mahidol University, Thailand). 🔗 ESMO session link: https://lnkd.in/dGWkW9Um 🔗 Read more about the symposium: https://lnkd.in/dfw2jFmW The symposium reflects Gene Solutions’ mission to make precision cell-free DNA testing accessible to millions of people across the cancer care continuum, so more people can receive an answer in time to act. Stay tuned for further symposium updates from Gene Solutions. #ESMO2026 #PrecisionOncology #LiquidBiopsy #MultiOmics #MCED #MRD #CGP #3Dorganoids #AI #RWE #cfDNA This non-promotional medical educational symposium is organized and funded by Gene Solutions for healthcare professionals only.